Quest, HealthTaps partner for virtual diagnostic testing

HealthTap and Quest Diagnostics will collaborate to enable doctors to order diagnostic testing services for patients through HealthTap’s comprehensive virtual care platform.

According to the announcement, this is the first partnership between a major national medical laboratory provider and an end-to-end virtual care company, which will enable doctors and consumers to access a broad range of diagnostic service options to help care for patients in a virtual setting.

HealthTap’s network of doctors will be able to seamlessly order laboratory testing for patients who seek virtual consults via HealthTap. Doctors will have access to Quest’s network of medical and scientific experts and comprehensive menu of diagnostic test services, including commonly ordered laboratory tests ranging from diabetes screening, cardiovascular risk assessment, hepatitis C screening, and tests for many other critical health conditions. 

“The future of healthcare is based on a deeper understanding of personal health data, and we’re excited to provide the technology infrastructure that will enable immediate, affordable, accessible, data driven care,” said Ron Gutman, HealthTap's CEO.    

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.